RecruitingPhase 3NCT07329777

Atropine in the Treatment of Myopia Study in Malaysia

Atropine in the Treatment of Myopia Study in Malaysia (ATOM-MY): A Randomized, Double-Blind Study to Demonstrate the Efficacy and Safety of Eye Drop Formulations (Atropine Sulphate 0.025 % w/v Eye Drops vs Placebo) in the Management of Controlling Progression of Myopia in Children.

Sponsor

IDB VisionCare SDN BHD

Enrollment

144 participants

Start Date

Sep 17, 2025

Study Type

INTERVENTIONAL

Conditions

Myopia Progression

Summary

This clinical trial is designed to assess the efficacy and safety of Atropine Sulphate 0.025% w/v Eye Drops compared to placebo in a randomized, double-blind, placebo-controlled study for the management of myopia progression in children.

Eligibility

Min Age: 5 YearsMax Age: 10 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Low dose atropine sulfate eye drops and a drug called Placebo for people with myopia progression. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 5 Years to 10 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.